Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
NNC4004-0002 · 1 trial · 2 indications
Count
| Arm | Type | Description |
|---|---|---|
| NNC4004-0002 | EXPERIMENTAL | Participants will receive a single dose of NNC4004-0002 injected subcutaneously. Trial will include up to 6 ascending single-dose cohorts. |
| Placebo | PLACEBO_COMPARATOR | Participants in each cohort will receive placebo matched to NNC4004-0002 injected subcutaneously. |
| Name | Type | Description |
|---|---|---|
| NNC4004-0002 | DRUG | NNC4004-0002 will be given as a single ascending dose via subcutaneous route. |
| Placebo | DRUG | Placebo matched to NNC4004-0002 will be given via subcutaneous route. |
Inclusion Criteria: * Males or females 35 to 75 years of age at the time of signing the informed consent form (ICF). * Considered to be generally healthy based on medical history, physical examination, and the re-sults of vital signs, electrocardiogram, and clinical laboratory tests performed durin...
NNC4004-0002 is an investigational small molecule being developed by Novo Nordisk A/S for hyperuricemia, a metabolic condition involving elevated uric acid levels. It is currently in Phase 1 clinical development and has not been approved for any indication.
NNC4004-0002 is being studied for the treatment of hyperuricemia. The only clinical trial to date is in participants with asymptomatic hyperuricemia, meaning elevated uric acid without symptoms. It is investigational and not approved for any use.
NNC4004-0002 is developed by Novo Nordisk A/S, which trades under the ticker NVO. Novo Nordisk is the sponsor of the Phase 1 trial evaluating the drug in asymptomatic hyperuricemia.
NNC4004-0002 is in Phase 1 clinical development. It is investigational and has not been approved by the FDA or any regulatory authority. The Phase 1 trial is currently recruiting participants.
NNC4004-0002 is being evaluated in one Phase 1 trial, NCT06859073, titled a study to evaluate the safety of NNC4004-0002 in participants with asymptomatic hyperuricemia. The trial is recruiting, with an estimated enrollment of 60 participants in the United States.
The Phase 1 trial NCT06859073 is a randomized, double-blind, placebo-controlled study. It plans to enroll 60 participants aged 35 years and older, including healthy volunteers, with asymptomatic hyperuricemia. The trial is recruiting in the United States.